Genfit shares rebound and gain 26.5% over one month on the SBF 120
The Lille-based biotech specialising in liver and metabolic diseases recovers mid-session in a Paris market trending higher. After a decline the previous day, the stock regains a solid position in the SBF 120 ranking, while questions arise about the continuation of a rebound begun at the end of October.
A rebound that puts the stock back above its moving averages
Genfit shares rise 2.11% to €10.64 intraday, while the SBF 120 gains 0.36%.
The stock ranks in the upper part of the index and remains up 26.67% over one month, even though it still falls 2.74% over seven days. This recovery is supported by a price that touches its MM20 at €10.62 (a gap of +0.19%) and remains above its MM50 at €10.05, with a gap of +5.87%.
The RSI at 53 remains neutral. The MACD, whose histogram is slightly negative, does not yet clearly confirm the momentum of recent weeks. The €11.46 resistance, already broken in early November, remains the reference level above the current price.
Sharp rise in Iqirvo royalties, but total revenue declines
In its publication of 5 November 2026 (nine-month figures), Genfit reported Iqirvo royalties up 188% to €36.3 million, while total revenue fell to €36.4 million from €39.2 million a year earlier.
The company then indicated that these elements reinforced its expectation of a possible new commercial milestone payment, and that its cash position would allow it to finance its activities beyond the end of 2028.
Among the risks cited on this occasion was dependence on Ipsen, which accounts for almost all of the royalties. Looking ahead, the reimbursement of the NASHnext test by Medicare, approved in August 2026, opens a market that the group estimates at more than $1.5 billion by 2033.
The stock had reacted in both directions to this publication before resuming its upward move. Earlier, on 8 November, Genfit detailed its strategy in ACLF, with first phase 2a data expected in 2027.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.